Cutler Group LP Janux Therapeutics, Inc. Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 400 shares of JANX stock, worth $21,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400Holding current value
$21,400% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
123Shares Held
25.3MCall Options Held
92KPut Options Held
161K-
Orbimed Advisors LLC San Diego, CA4.28MShares$229 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$156 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$148 Million0.2% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.35MShares$126 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$105 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.23B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...